Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
150 hedge funds and large institutions have $885M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 59 increasing their positions, 34 reducing their positions, and 12 closing their positions.
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
74% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 34
63% more capital invested
Capital invested by funds: $545M → $885M (+$341M)
17% more funds holding
Funds holding: 128 → 150 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$24.2M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$10.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$9.79M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$59M |
| 2 |
State Street
Boston,
Massachusetts
|
-$11.2M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.8M |
| 4 |
AC
Armistice Capital
New York
|
-$9.92M |
| 5 |
JG
Jefferies Group
New York
|
-$8.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
151
Laurion Capital Management
New York
| – | -$4.71M | -358,380 | Closed |
|
152
Renaissance Technologies
New York
| – | -$1.17M | -88,900 | Closed |
|
|
E
153
Ergoteles
New York
| – | -$743K | -56,500 | Closed |
|
|
SO
154
STRS Ohio
Columbus,
Ohio
| – | -$628K | -47,800 | Closed |
|
|
EMG
155
ETF Managers Group
Summit,
New Jersey
| – | -$373K | -27,678 | Closed |
|
|
YIH
156
Y-Intercept (HK)
Hong Kong
| – | -$245K | -18,651 | Closed |
|
|
DA
157
Denali Advisors
San Diego,
California
| – | -$104K | -7,900 | Closed |
|
158
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$14K | -1,039 | Closed |
|
|
AI
159
AdvisorShares Investments
Bethesda,
Maryland
| – | -$9K | -718 | Closed |
|
|
LSA
160
Leonteq Securities AG
Zurich,
Switzerland
| – | -$2.63K | -200 | Closed |
|
|
NFSG
161
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$1K | -98 | Closed |
|
162
Group One Trading
Chicago,
Illinois
| – | -$16 | -1 | Closed |
|
DCPH Hedge Fund Activity: Q3 2022 in Review
150 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2022, worth a combined $885M — up 63% from $545M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new DCPH positions and 12 closed out — a net gain of 22 holders — while 59 added to existing stakes and 34 trimmed.
The largest buyer was Redmile Group, adding an estimated $24.2M. The largest seller was Deerfield Management, cutting an estimated $59M.
- 150 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2022, up from 128 in Q2 2022.
- Funds reported $885M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2022, up 63% quarter-over-quarter.
- 34 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of +22 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2022 was Redmile Group, an estimated $24.2M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2022 was Deerfield Management, an estimated $59M sold.
Based on aggregated 13F filings for Q3 2022.